Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for secondary prevention in stable coronary artery disease
ACTRN12610000293066Phase 3Completed
- Sponsor
- Mark Nidorf
- Start
- Sep 2008
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of colchicine in coronary arteriosclerosis (2 arms), sponsored by Mark Nidorf. Primary endpoint: Major adverse cardiac or cerebrovascular events. Started Sep 2008; status: completed.
02
Drugs
colchicine
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ACTRN12610000293066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000293066.